The University of Southampton
University of Southampton Institutional Repository

Recombinant growth hormone for children and adolescents with Turner syndrome.

Recombinant growth hormone for children and adolescents with Turner syndrome.
Recombinant growth hormone for children and adolescents with Turner syndrome.
Recombinant human growth hormone (hGH) doses between 0.3 to 0.375 mg/kg/wk increase short-term growth in girls with Turner syndrome by approximately three (two) cm in the first (second) year of treatment. Treatment in one trial increased final height by approximately six cm over an untreated control group. Despite this increase, the final height of treated women was still outside the normal range. Additional trials of the effects of hGH carried out with control groups until final height is achieved would allow better informed decisions about whether the benefits of hGH treatment outweigh the requirement of treatment over several years at considerable cost.
1465-1858
CD003887
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Bryant, J.
508f497c-8b5a-468f-a37d-be9c26e4e49d
Cave, C.B.
e1e8cf36-a670-4655-86b2-b15803a67489
Milne, R.
bd90470b-bba2-49a1-aa12-f1319d78afc2
Baxter, L.
eeafbfe7-ae7e-421f-a6b6-c6d9df80b6ef
Bryant, J.
508f497c-8b5a-468f-a37d-be9c26e4e49d
Cave, C.B.
e1e8cf36-a670-4655-86b2-b15803a67489
Milne, R.
bd90470b-bba2-49a1-aa12-f1319d78afc2

Baxter, L., Bryant, J., Cave, C.B. and Milne, R. (2007) Recombinant growth hormone for children and adolescents with Turner syndrome. The Cochrane Library, (1), CD003887. (doi:10.1002/14651858.CD003887.pub2). (PMID:12917993)

Record type: Article

Abstract

Recombinant human growth hormone (hGH) doses between 0.3 to 0.375 mg/kg/wk increase short-term growth in girls with Turner syndrome by approximately three (two) cm in the first (second) year of treatment. Treatment in one trial increased final height by approximately six cm over an untreated control group. Despite this increase, the final height of treated women was still outside the normal range. Additional trials of the effects of hGH carried out with control groups until final height is achieved would allow better informed decisions about whether the benefits of hGH treatment outweigh the requirement of treatment over several years at considerable cost.

Text
pdf - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: 29 January 2007
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 345444
URI: https://eprints.soton.ac.uk/id/eprint/345444
ISSN: 1465-1858
PURE UUID: 3a17fb07-e075-4c5b-a1e5-7726e1808f58
ORCID for R. Milne: ORCID iD orcid.org/0000-0002-5117-4380

Catalogue record

Date deposited: 20 Nov 2012 16:25
Last modified: 20 Jul 2019 01:12

Export record

Altmetrics

Contributors

Author: L. Baxter
Author: J. Bryant
Author: C.B. Cave
Author: R. Milne ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×